Vigil Neuroscience Inc
VIGL8.065USD
+0.015+0.19%
Market hours （ET）Quotes delayed by 15 min
376.41MMarket Cap
LossP/E TTM
More Details of Vigil Neuroscience Inc Company
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.
Company Info
Ticker SymbolVIGL
Company nameVigil Neuroscience Inc
IPO dateJan 07, 2022
CEODr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Number of employees69
Security typeOrdinary Share
Fiscal year-endJan 07
Address100 Forge Road
CityWATERTOWN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02472
Phone18572544445
Websitehttps://www.vigilneuro.com/
Ticker SymbolVIGL
IPO dateJan 07, 2022
CEODr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Samantha Budd Haeberlein, Ph.D.
Dr. Samantha Budd Haeberlein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
Independent Director
Independent Director
--
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Petra Kaufmann, M.D.
Ms. Petra Kaufmann, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David Gray, Ph.D.
Dr. David Gray, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Gerhard Koenig, Ph.D.
Dr. Gerhard Koenig, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jennifer Ziolkowski, CPA
Ms. Jennifer Ziolkowski, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stefan Vitorovic
Mr. Stefan Vitorovic
Independent Director
Independent Director
--
-100.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Samantha Budd Haeberlein, Ph.D.
Dr. Samantha Budd Haeberlein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
Independent Director
Independent Director
--
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Petra Kaufmann, M.D.
Ms. Petra Kaufmann, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 1
Updated: Fri, Aug 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Atlas Venture
12.51%
Beryl Capital Management, LLC
9.87%
BVF Partners L.P.
8.60%
Amgen Inc
6.87%
Glazer Capital, LLC
5.39%
Other
56.77%
Shareholders
Shareholders
Proportion
Atlas Venture
12.51%
Beryl Capital Management, LLC
9.87%
BVF Partners L.P.
8.60%
Amgen Inc
6.87%
Glazer Capital, LLC
5.39%
Other
56.77%
Shareholder Types
Shareholders
Proportion
Hedge Fund
33.86%
Venture Capital
17.21%
Investment Advisor
11.63%
Corporation
6.87%
Investment Advisor/Hedge Fund
3.73%
Individual Investor
0.51%
Research Firm
0.40%
Bank and Trust
0.17%
Other
25.62%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
167
34.72M
74.40%
-8.46M
2025Q1
155
37.71M
83.92%
-8.48M
2024Q4
145
40.31M
98.61%
+1.04M
2024Q3
142
37.92M
96.31%
-1.37M
2024Q2
139
36.35M
96.29%
-1.95M
2024Q1
131
36.78M
100.64%
+157.59K
2023Q4
124
35.04M
97.83%
-1.22M
2023Q3
117
35.82M
100.15%
-590.79K
2023Q2
111
36.00M
101.04%
+568.49K
2023Q1
103
35.28M
105.30%
-113.43K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Atlas Venture
5.84M
12.51%
--
--
Jun 11, 2025
Beryl Capital Management, LLC
4.61M
9.87%
+4.61M
--
May 22, 2025
BVF Partners L.P.
4.01M
8.6%
+2.20M
+121.30%
Mar 31, 2025
Amgen Inc
3.21M
6.87%
--
--
Jun 11, 2025
Glazer Capital, LLC
2.51M
5.39%
+2.51M
--
May 28, 2025
Invus Public Equities Advisors, LLC
1.97M
4.21%
-23.97K
-1.20%
Mar 31, 2025
683 Capital Management LLC
1.74M
3.73%
+340.00K
+24.29%
Mar 31, 2025
VV Manager LLC
1.63M
3.5%
-3.38M
-67.41%
Jun 11, 2025
Sphera Funds Management Ltd.
1.60M
3.44%
+102.00K
+6.79%
Mar 31, 2025
Ensign Peak Advisors, Inc.
1.58M
3.38%
+875.00K
+124.45%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
NYLI Merger Arbitrage ETF
0.2%
iShares Health Innovation Active ETF
0.1%
iShares Micro-Cap ETF
0.05%
Avantis US Small Cap Equity ETF
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
View more
NYLI Merger Arbitrage ETF
Proportion0.2%
iShares Health Innovation Active ETF
Proportion0.1%
iShares Micro-Cap ETF
Proportion0.05%
Avantis US Small Cap Equity ETF
Proportion0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
